SPONSOR
Fujian Cancer Hospital
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2, Phase 2, Phase 3
Fujian Cancer Hospital is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Advanced Triple Negative Breast Cancer, Immunotherapy Gastrict Cancer.
The trial portfolio spans Phase 1, Phase 2, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Fujian Cancer Hospital
How many clinical trials has Fujian Cancer Hospital sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Fujian Cancer Hospital, of which 2 are actively recruiting participants. These trials cover conditions including Advanced Triple Negative Breast Cancer, Immunotherapy Gastrict Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Fujian Cancer Hospital research focus on?
Fujian Cancer Hospital clinical trials span Advanced Triple Negative Breast Cancer, Immunotherapy Gastrict Cancer. The research pipeline includes Phase 1, Phase 2, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Fujian Cancer Hospital clinical trial?
To participate in a Fujian Cancer Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fujian Cancer Hospital trials with current recruitment status updated daily.
Clinical Trials by Fujian Cancer Hospital
NCT05019690 Phase 1, Phase 2
Recruiting
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Advanced Triple Negative Breast Cancer
NCT05699655 Phase 2, Phase 3
Recruiting
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Immunotherapy Gastrict Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology